LATEST RESEARCH NEWS BY ONCOTARGET:
- Does a Mechanism Linking Cellular Aging to Cellular Quiescence Exist?Researchers found that diverse geroprotectors differently affect a mechanism linking cellular aging to cellular quiescence in budding yeast.
- How Heartburn Can Turn Into Esophageal Cancer, and a Possible BiomarkerIn a recent Oncotarget paper, researchers investigated telomere shortening in patients with Barrett’s esophagus as a potential biomarker of high risk for esophageal cancer.
- New Tool Uses NF-κB Activity to Classify HPV+ Head and Neck CancerResearchers developed a new tool aimed at better classifying HPV+ HNSCC patients with good or poor prognosis in an effort to personalize treatment and improve patient outcomes.
Oncotarget.org publishes weekly articles describing new and trending research papers published by Oncotarget—an open access biomedical journal dedicated to the publishing of the latest oncology-focused, peer-reviewed research papers. Visit Oncotarget.net to hear directly from the distinguished network of authors who continue to publish their research with Oncotarget. Readers may also find information about community news and events sponsored by Oncotarget at Oncotarget.net.
Oncotarget is published by Impact Journals, based out of Orchard Park, New York. Impact Journals has a proven track record for reaching the standards of the Wellcome Trust Publisher Requirements and is included in their Wellcome Trust List of Compliant Publishers. Read about our rigorous Scientific Integrity Process.
The Editorial Board of Oncotarget is honored to feature several Nobel Prize winners. The Editorial Board also features winners of prestigious recognitions such as the Lasker Award and the Breakthrough Prize.
Oncotarget utilizes an open-access model. This means that the peer-reviewed research articles published in Oncotarget are distributed online, free of cost or other access barriers. Oncotarget’s mission has always been to make exceptional discoveries rapidly and widely available, eliminate borders between specialties by linking different fields of biomedical science to foster the applications of basic and clinical science.
Dr. Blagosklonny and Dr. Gudkov are the two founding Editors-in-Chief of Oncotarget. They both have a history of producing some of the finest medical research. Dr. Gudkov is focusing on developing and applying new technologies for functional gene discovery, which will lead to designing new therapeutic approaches to cancer treatment. Dr. Blagosklonny, well-known for his expertise in cancer and aging research. He has published dozens of experimental and theoretical papers that encompassed two important subjects: selective killing cancer cells with deregulated cell cycle or drug resistance by exploiting their resistance and the hyperfunction (or quasi-programmed) theory of aging. In its turn, this theory helped to rediscover Rapamycin as a well-tolerated anti-aging drug.
For media inquiries, please contact email@example.com.